HHS selects intranasal vaccine candidates for Project NextGen, doles out $500M in fundsnews2023-10-13T18:25:33+00:00October 13th, 2023|Endpoints News|
Exclusive: Horizon CEO Tim Walbert talks M&A, FTC post-Amgen deal closenews2023-10-13T18:23:41+00:00October 13th, 2023|Endpoints News|
Relay Therapeutics points to drug price negotiations for delay in potential blockbuster cancer drugnews2023-10-13T18:05:06+00:00October 13th, 2023|Endpoints News|
Novo Nordisk raises 2023 financial guidance thanks to Ozempic and Wegovy sales in the USnews2023-10-13T17:38:38+00:00October 13th, 2023|Endpoints News|
Sotio terminates three trials studying its IL-15 superagonist due to ‘insufficient efficacy’news2023-10-13T17:25:34+00:00October 13th, 2023|Endpoints News|
OptimizeRx builds out patient marketing services with $95M acquisitionnews2023-10-13T16:58:22+00:00October 13th, 2023|Endpoints News|
BIO, PhRMA, others seek tweaks to FDA draft guidance on diversity in postmarketing studiesnews2023-10-13T16:15:26+00:00October 13th, 2023|Endpoints News|
Biotech in Israel: Holding on to business as usual amid uncertain timesnews2023-10-13T15:07:51+00:00October 13th, 2023|Endpoints News|
Harmony Biosciences’ Wakix fails PhIII hypersomnia study; Florida gene therapy startup downsizesnews2023-10-13T15:06:59+00:00October 13th, 2023|Endpoints News|
Sanofi’s atopic dermatitis drug amlitelimab hits primary endpoint, on its way to PhIII trialnews2023-10-13T14:00:17+00:00October 13th, 2023|Endpoints News|
